Journal article
Phase 2 Study of the Factor XI Antisense Inhibitor IONIS-FXIRx in Patients With ESRD
Abstract
INTRODUCTION: Patients with end-stage renal disease (ESRD) requiring hemodialysis (HD) have an increased risk of thrombotic events and bleeding. Antisense reduction of factor XI (FXI) with IONIS-FXIRx is a novel strategy that may safely reduce the risk of thrombotic events.
METHODS: This multicenter study enrolled 49 patients receiving HD in 2 parts. First, 6 participants (pharmacokinetics [PK] cohort) received 1 open-label 300 mg dose of …
Authors
Walsh M; Bethune C; Smyth A; Tyrwhitt J; Jung SW; Yu RZ; Wang Y; Geary RS; Weitz J; Bhanot S
Journal
Kidney International Reports, Vol. 7, No. 2, pp. 200–209
Publisher
Elsevier
Publication Date
February 2022
DOI
10.1016/j.ekir.2021.11.011
ISSN
2468-0249